Near-Infrared Fluorescent Sentinel Lymph Node Mapping for Breast Cancer

Completed · Phase 1

Conditions studied: Breast Cancer

In brief

Sentinel lymph node (SLN) mapping is the standard of care for the surgical staging of breast cancer. We propose a method of SLN mapping based on the use of invisible near-infrared fluorescent light that has significant advantages for both patient and surgeon. The present study is a 6-patient pilot study designed to optimize clinical workflow with the new imaging system.

Key facts

Study ID

NCT00721370

Run by

Beth Israel Deaconess Medical Center

People needed

12

Starts

2008-07-01

Expected to finish

2011-01-01

Last updated by the study team

2013-02-18

Who can join

Age: 21 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Women or men above the age of 21 who have biopsy-proven breast cancer, and who are undergoing sentinel lymph node mapping for staging and treatment of their disease.

You may not qualify if…

• Pregnant women,
• Significant renal, cardiac, or pulmonary disease,
• History of iodine allergy.

Where it is running

• Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.